Cedar Pollen Allergy – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Cedar Pollen Allergy – Pipeline Review, H2 2016’, provides an overview of the Cedar Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy

The report reviews pipeline therapeutics for Cedar Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cedar Pollen Allergy therapeutics and enlists all their major and minor projects

The report assesses Cedar Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello A/S

Astellas Pharma Inc.

Circassia Pharmaceuticals Plc

Immunomic Therapeutics, Inc.

Japan Tobacco Inc.

REGiMMUNE Corporation

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cedar Pollen Allergy Overview 6

Therapeutics Development 7

Pipeline Products for Cedar Pollen Allergy - Overview 7

Pipeline Products for Cedar Pollen Allergy - Comparative Analysis 8

Cedar Pollen Allergy - Therapeutics under Development by Companies 9

Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 10

Cedar Pollen Allergy - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Cedar Pollen Allergy - Products under Development by Companies 14

Cedar Pollen Allergy - Products under Investigation by Universities/Institutes 15

Cedar Pollen Allergy - Companies Involved in Therapeutics Development 16

ALK-Abello A/S 16

Astellas Pharma Inc. 17

Circassia Pharmaceuticals Plc 18

Immunomic Therapeutics, Inc. 19

Japan Tobacco Inc. 20

REGiMMUNE Corporation 21

Cedar Pollen Allergy - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Combination Products 23

Assessment by Target 24

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

ASP-4070 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Biologic for Cedar Pollen Allergy - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

JCC-LAMP-Vax - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

RGI-1001 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

TO-206 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Vaccine for Cedar Pollen Allergy - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Vaccine for Japanese Cedar Pollen Allergy - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Cedar Pollen Allergy - Dormant Projects 42

Cedar Pollen Allergy - Product Development Milestones 43

Featured News & Press Releases 43

Aug 07, 2015: ALK’s partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet 43

Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference 43

Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 43

Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy 44

Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

List of Tables

Number of Products under Development for Cedar Pollen Allergy, H2 2016 7

Number of Products under Development for Cedar Pollen Allergy – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Cedar Pollen Allergy – Pipeline by ALK-Abello A/S, H2 2016 16

Cedar Pollen Allergy – Pipeline by Astellas Pharma Inc., H2 2016 17

Cedar Pollen Allergy – Pipeline by Circassia Pharmaceuticals Plc, H2 2016 18

Cedar Pollen Allergy – Pipeline by Immunomic Therapeutics, Inc., H2 2016 19

Cedar Pollen Allergy – Pipeline by Japan Tobacco Inc., H2 2016 20

Cedar Pollen Allergy – Pipeline by REGiMMUNE Corporation, H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Assessment by Combination Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Cedar Pollen Allergy – Dormant Projects, H2 2016 42

List of Figures

List of Figures

Number of Products under Development for Cedar Pollen Allergy, H2 2016 7

Number of Products under Development for Cedar Pollen Allergy – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports